Joël Ménard. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Angiotensin II/immunologyAngiotensin II Type 1 Receptor Blockers/pharmacologyAngiotensin II Type 1 Receptor Blockers/therapeutic useAngiotensin-Converting Enzyme Inhibitors/pharmacologyAngiotensin-Converting Enzyme Inhibitors/therapeutic useAnimalsAntihypertensive Agents/historyAntihypertensive Agents/pharmacologyAntihypertensive Agents/therapeutic useBiomedical Research/ethicsClinical Trials as Topic/ethicsHistory, 20th CenturyHumansHypertension/drug therapyHypertension/historyHypertension/physiopathologyRenin-Angiotensin System/drug effectsRenin-Angiotensin System/immunologyVaccines/historyVaccines/therapeutic use
Substances: See more » Angiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsVaccinesAngiotensin II
Year: 2007 PMID: 17143170 DOI: 10.1097/HJH.0b013e328012981b
Source DB: PubMed Journal: J Hypertens ISSN: 0263-6352 Impact factor: 4.844